Patents Assigned to MEREO BIOPHARMA 3 LIMITED
-
Publication number: 20230365669Abstract: Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.Type: ApplicationFiled: April 7, 2023Publication date: November 16, 2023Applicant: MEREO BIOPHARMA 3 LIMITEDInventors: Uwe JUNKER, Michaela KNEISSEL, Anthony Kent HALL, Rena Joy EUDY, Matthew Manning RIGGS
-
Publication number: 20210253684Abstract: Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.Type: ApplicationFiled: December 30, 2020Publication date: August 19, 2021Applicant: MEREO BIOPHARMA 3 LIMITEDInventors: Uwe JUNKER, Michaela KNEISSEL, Anthony Kent HALL, Rena Joy EUDY, Matthew MANNING RIGGS
-
Publication number: 20210198350Abstract: The present invention relates to methods and compositions for treating a myopathy in a subject, comprising administering a therapeutically effective amount of a sclerostin antagonist to the subject. The myopathy may be characterized by a loss of skeletal muscle mass, size, strength and/or function. The sclerostin antagonist may be an anti-sclerostin antibody.Type: ApplicationFiled: June 28, 2019Publication date: July 1, 2021Applicant: MEREO BIOPHARMA 3 LIMITEDInventors: Eric HESSE, Hanna TAIPALEENMAKI
-
Patent number: 10961305Abstract: Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.Type: GrantFiled: December 21, 2017Date of Patent: March 30, 2021Assignee: MEREO BIOPHARMA 3 LIMITEDInventors: Uwe Junker, Michaela Kneissel, Anthony Kent Hall, Rena Joy Eudy, Matthew Manning Riggs
-
Publication number: 20200179509Abstract: Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.Type: ApplicationFiled: December 21, 2017Publication date: June 11, 2020Applicant: MEREO BIOPHARMA 3 LIMITEDInventors: Uwe JUNKER, Michaela KNEISSEL, Anthony Kent HALL, Rena Joy EUDY, Matthew MANNING RIGGS
-
Publication number: 20200123242Abstract: Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.Type: ApplicationFiled: January 2, 2020Publication date: April 23, 2020Applicant: MEREO BIOPHARMA 3 LIMITEDInventors: Uwe JUNKER, Michaela KNEISSEL, Anthony Kent HALL, Rena Joy EUDY, Matthew MANNING RIGGS
-
Publication number: 20190330322Abstract: Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.Type: ApplicationFiled: December 21, 2017Publication date: October 31, 2019Applicant: MEREO BIOPHARMA 3 LIMITEDInventors: Uwe JUNKER, Michaela KNEISSEL, Anthony Kent HALL, Rena Joy EUDY, Matthew Manning RIGGS